2021
DOI: 10.1097/cm9.0000000000001846
|View full text |Cite
|
Sign up to set email alerts
|

Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 51 publications
0
3
0
Order By: Relevance
“…In this study, the TNF-α concentration was also measured in our study and showed no change in the rats with a neoplastic process (20.26 ± 3.79 pg/mL) as compared with the TNF-αRMK1 is an inflammatory cytokine produced during acute inflammation and is responsible for a diverse range of signaling events within cells, leading to necrosis or apoptosis [36][37][38].…”
Section: Resultsmentioning
confidence: 51%
See 2 more Smart Citations
“…In this study, the TNF-α concentration was also measured in our study and showed no change in the rats with a neoplastic process (20.26 ± 3.79 pg/mL) as compared with the TNF-αRMK1 is an inflammatory cytokine produced during acute inflammation and is responsible for a diverse range of signaling events within cells, leading to necrosis or apoptosis [36][37][38].…”
Section: Resultsmentioning
confidence: 51%
“…Blocking TNF-α activity was discovered to reduce the toxicity and may enhance the therapeutic effect of immune checkpoint inhibitors [ 42 , 43 , 44 ]. At the same time, the cytokine was found to show cancer-promoting effects [ 37 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation